A Comparative Study: Are Cryopreserved Leukopaks a Viable Alternative to Fresh?
The development of next-generation cell and gene therapies depends heavily on access to high-quality starting material. Although freshly isolated starting materials are considered the accepted standard, cryopreserved leukapheresis collections can provide a stable alternative to fresh; offering the same high-quality, and allowing the flexibility and consistency needed to plan and coordinate downstream activities with less disruptions.
This white paper will discuss:
- A HemaCare-sponsored study demonstrating how cryopreservation can preserve WBC yields and viability, and maintain therapeutic cell ratios comparable to freshly isolated leukopaks
- Best practices for the storage and handling of cryopreserved leukopaks
- How cryopreservation simplifies complex logisitics making downstream activities easier to manage